September 18,The Development and Reform Commission issued a notice of adjusting drug prices such as anti -tumor,Adjust part of the anti -tumor from October 8th、The maximum retail price limit of drugs such as immune and blood system category,The average price Stake Sports Bettingreduction My stake betting appis 17%. Previous,The sound of tumor drug price adjustment has been constantly,This time the Development and Reform Commission issued a post can be described as the boots landed。Relevant persons of listed companies think,The price reduction is not expected to surpass this time,Therefore, there is not much impact。

    Researcher: help reduce the burden on patients

    "Daily Economic News" reporter noticed,This price adjustment is not the first time the Development and Reform Commission has lowered drug prices。May 1 this year,The Development and Reform Commission has adjusted some of the digestive system drugs for the highest retail price limit,involved 53 varieties,More than 300 dosage specifications,The average decrease is also 17%.

    Researcher Guo Fanli, a researcher at the pharmaceutical industry of China Investment Consultant, said in an interview with the reporter of "Daily Economic News",This price adjustment mainly involves anti -tumor medication,The characteristics of such drugs are that the treatment cycle is relatively long,Therefore, for related patients,The influence is still relatively large,Lives the burden of medical expenses of ordinary people。

    Guo Jin Securities Analyst Li Jinglei said,Generally speaking,The actual market Stake Sports Bettingstake sports betting appprice of the drug is determined by the bidding of all provinces,and will be lower than the highest retail price limit。

    Shanghai Rice: It has a little impact on this year's performance

    The price reduction variety includes,Anti -tumor medicine、Blood Products、Immunosis medicine,involved a lot of listed companies。Anti -tumor drug listed company includes Hengrui Pharmaceutical (600276,The closing price is 30.03 yuan)、Haizheng Pharmaceutical (600267,The closing price is 15.40 yuan)、Shuanglu Pharmaceutical (002038,closing price of 35.85 yuan)、East China Pharmaceutical (000963,closing price of 35.45 yuan), etc.; blood products listed companies include Shanghai Rice (002252,closing price 12.85 yuan)、Hualan Bio (002007,The closing price is 26.07 yuan)、Boya Bio (300294,closing price of 32.64 yuan); immune category is East China Medicine、North China Pharmaceutical (600812,The closing price is 6.10 yuan), etc.。

    The effect on this price reduction,The reporter interviewed relevant listed companies。Hengrui Pharmaceutical Dai Hongbin told the reporter of "Daily Economic News",The price reduction is within the acceptable range; Zhang Yi, representative of Shanghai Rice Securities Stake Sports Bettingstake online sports bettingAffairs, said,The price reduction catalog announced by the Development and Reform Commission is related to its company,That is the intravenous injection of the employment immunoglobulin,Human Fibrobinyuan,Human coagulation factor。Among them, the last two products are sold at this price (maximum retail price) before the price reduction,Therefore, the price reduction has little effect; the only influence is intravenous injection of employment immunoglobulin,Before Shanghai, 2.5g: 50ml Varicose injection of the employer immunoglobulin maximum retail limit price of 600 yuan/support,Now it is reduced to 561 yuan/support。But since the price reduction starts from October 8th,In the first three quarters, the previous price was performed,Therefore, it has little impact on this year's performance。